Author Correction: Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double

Subjects
Correction to: Nature Medicine https://doi.org/10.1038/s41591-026-04479-3 published online 7 June 2026
In the version of the article initially published, among the SYNCHRONIZE-MASLD Investigators, Juan M. Pericás (Liver Unit, Vall d’Hebron University Hospital, VHIR, Universitat Autònoma de Barcelona, CIBERehd, Barcelona, Spain) and Michael Zimmerman (Velocity Clinical Research, Austin, TX, USA) were not included in the author list; Antonio Olveira (Hospital Universitario La Paz, Madrid, Spain) was listed with an incorrect surname (Antonio O. Martin) and an incorrect additional affiliation; and Rizwana Mohseni was listed with an incorrect second affiliation. In the “Participants” section of Results, there was a typographical error: in the sentence now reading “Treatment discontinuation occurred at a similar frequency in the survodutide (41.1% (60/146)) and placebo (40.0% (28/70)) arms,” “70” originally appeared as “72.” Additionally, in the caption to Extended Data Fig. 5, “week 52” now replaces the original “week 48.” The changes have been made in the HTML and PDF versions of the article.
Author information
Authors and Affiliations
Consortia
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/
About this article
Cite this article
Kaplan, L.M., Startseva, E., le Roux, C.W. et al. Author Correction: Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial. Nat Med (2026). https://doi.org/10.1038/s41591-026-04650-w
Published:
Version of record:
DOI: https://doi.org/10.1038/s41591-026-04650-w

* Correction made to the author list: Juan M. Pericás and Michael Zimmerman were omitted from the original listing.
* Correction made to Antonio Olveira's name and affiliation details.
* Correction made to Rizwana Mohseni's second affiliation.
* Typographical error in Results: Treatment discontinuation frequency cited 72 instead of 70 for survodutide group, and 70 instead of 72 for placebo group.
* Caption change: Extended Data Fig. 5 updated "week 52" to "week 48."
* Article DOI: 10.1038/s41591-026-04650-w.

The publication involves a correction to an article titled "Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial." Several authorship and typographical errors were identified and corrected. Specifically, Juan M. Pericás and Michael Zimmerman were omitted from the original author list; Antonio Olveira's surname and affiliation were incorrect; Rizwana Mohseni had an incorrect second affiliation; a typo in the "Participants" section of Results incorrectly cited "72" instead of "70" regarding treatment discontinuation frequency in the survodutide and placebo arms; and in the caption for Extended Data Fig. 5, "week 52" was changed to "week 48."

The process of correcting errors in published scientific literature highlights the fragility of data integrity and the complexity of academic dissemination. The required revisions, involving authorship placement and specific numerical details within results and figures, illustrate that scientific truth is not static but relies on meticulous, human oversight during the publishing lifecycle. This points to systemic vulnerabilities in the peer review or editorial workflow where small administrative errors can surface as significant factual deviations. The pattern observed is that complexity often masks fragility; detailed findings require equally detailed administrative rigor to ensure their transfer of meaning is accurate. The implication for cognitive sovereignty is recognizing that reliance on published knowledge necessitates a vigilance against superficial detail, as even corrected facts rely on the initial vulnerability being identified. What processes govern this level of meticulousness across large-scale collaborative trials? How can systems be designed to institutionalize error detection beyond simple textual review?

Author Correction: Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double

Facts Only

Executive Summary

Full Take

Sentinel — Human

Author Correction: Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double

Facts Only

Executive Summary

Full Take

Sentinel — Human